Hepatoprotective Effects of a Novel Trihoney against Nonalcoholic Fatty Liver Disease: A Comparative Study with Atorvastatin

Table 4

Effect of Trihoney on activities of SOD and GPx and on MDA concentration in liver homogenate of NAFLD at week 12.

Group	SOD activity (%)	GPx activity (mU/mg protein)	MDA (µg/mg protein)
C	61.43 ± 2.69	109.88 ± 40.44	0.00 ± 0.00
C + H	46.89 ± 2.44	90.97 ± 37.26	0.03 ± 0.01
HCD	27.98 ± 7.05^a,b∗∗∗	49.98 ± 36.40^a∗	0.98 ± 0.17^a,b∗∗∗
HCD + H1	50.95 ± 5.15^a∗^,c∗∗∗	95.68 ± 13.77	0.31 ± 0.12^a,b∗∗^,c∗∗∗
HCD + H2	29.89 ± 10.62^a∗∗∗^,b∗∗^,d∗∗∗	72.45 ± 22.16	0.14 ± 0.04^c∗∗∗^,d∗
HCD + At.	26.43 ± 5.49^a,b,d∗∗∗	37.45 ± 33.66^a^,b∗^,d∗	0.08 ± 0.13^c∗∗∗^,d∗∗

Values are mean ± standard deviation (SD) of the mean. The results of all experiment groups were analysed using one-way analysis of variance (ANOVA), followed by LSD post hoc test. Mean difference is considered significant at . ^aSignificant different from the C group; ^bsignificant different from the C + H group; ^csignificant different from the HCD group; ^dsignificant different from the HCD + H₁ group. ^∗; ^∗∗; ^∗∗∗.